AMT-130 Approval Will Transform Huntington's Treatment Pipeline

Published
11 May 25
Updated
01 Aug 25
AnalystConsensusTarget's Fair Value
US$33.44
60.3% undervalued intrinsic discount
01 Aug
US$13.28
Loading
1Y
83.9%
7D
-3.6%

Author's Valuation

US$33.4

60.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 Aug 25
Fair value Decreased 5.85%

Despite a sharp upward revision in revenue growth forecasts, a significant decline in net profit margin has led to a lower consensus analyst price target for uniQure, which has fallen from $35.51 to $33.44. What's in the News uniQure filed a follow-on equity offering of $200 million through an at-the-market ordinary share issuance.